Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database

BACKGROUND: Vascular endothelial growth factor (VEGF), tyrosine kinase (TK) and mechanistic target of rapamycin kinase (mTOR) inhibitors are common first-line (1 L) treatments for metastatic renal cell carcinoma (mRCC). Despite treatment availability, the 5-year survival rate in patients diagnosed a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Pal, Sumanta, Gong, Jun, Mhatre, Shivani K., Lin, Shih-Wen, Surinach, Andy, Ogale, Sarika, Vohra, Rini, Wallen, Herschel, George, Daniel
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6555983/
https://ncbi.nlm.nih.gov/pubmed/31174493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5716-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky